Tags : Nuzyra

Paratek’s Reports Results of Nuzyra (Omadacycline) in P-III OPTIC and

Shots: The P-III OPTIC and OASIS-1 studies involves assessing of Nuzyra (Omadacycline) vs moxifloxacin & linezolid in 386 & 645 patients with community acquired bacterial pneumonia (CABP) & acute bacterial skin and skin structure infections (ABSSSI) respectively OPTIC study results: ECR (81.1, vs 82.7%,); IACR @PTE (87.6%, vs 85.1%); TEAEs (6.0% vs 6.7%); OASIS-1 study: […]Read More

Paratek Pharmaceuticals’ Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial

Shots: The approval is based on multiple trial study assessing Nuzyra and resulted in safe, efficacious and well tolerated results Nuzyra (omadacycline) is a qd IV PO tetracycline class antibacterial drug indicated to treat CABP and  ABSSSI Post marketing approval, Paratek’s plans to evaluate Nuzyra for the treatment of CABP and pediatrics, with its expected […]Read More